$1.48
3.27% today
Nasdaq, Feb 05, 04:21 pm CET
ISIN
US0345691036
Symbol
ANEB
Sector
Industry

Anebulo Pharmaceuticals Inc Stock price

$1.53
-0.09 5.55% 1M
-0.39 20.31% 6M
-0.15 8.93% YTD
-1.03 40.23% 1Y
-5.64 78.66% 3Y
-5.47 78.14% 5Y
-5.47 78.14% 10Y
Nasdaq, Closing price Tue, Feb 04 2025
-0.07 4.38%
ISIN
US0345691036
Symbol
ANEB
Sector
Industry

Key metrics

Market capitalization $62.86m
Enterprise Value $61.46m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 20.90
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-8.18m
Free Cash Flow (TTM) Free Cash Flow $-7.05m
Cash position $1.40m
EPS (TTM) EPS $-0.31
Short interest 0.28%
Show more

Is Anebulo Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

Anebulo Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Anebulo Pharmaceuticals Inc:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Anebulo Pharmaceuticals Inc:

Buy
100%

Financial data from Anebulo Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 4.58 4.58
25% 25%
-
- Research and Development Expense 3.59 3.59
36% 36%
-
-8.18 -8.18
30% 30%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -8.18 -8.18
30% 30%
-
Net Profit -7.92 -7.92
32% 32%
-

In millions USD.

Don't miss a Thing! We will send you all news about Anebulo Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Anebulo Pharmaceuticals Inc Stock News

Neutral
Business Wire
about one month ago
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals Announces Positive Regulatory Update for Selonabant in Acute Cannabis-Induced Toxicity in Children and Capital Raise.
Neutral
Business Wire
3 months ago
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2025 Financial Results and Recent Updates.
Neutral
Business Wire
4 months ago
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Recent Updates.

Company Profile

Anebulo Pharmaceuticals, Inc. engages in the provision of pharmaceutical services. The firm product candidate is ANEB-001, a potent, small molecule cannabinoid receptor antagonist, designed to address the unmet medical need for a specific antidote for cannabinoid overdose. The company was founded by Lawyer Joseph F on April 23, 2020 and is headquartered in Lakeway, TX.

Head office United States
CEO Richard Cunningham
Employees 3
Founded 2020
Website www.anebulo.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today